Kayti Aviano
Chief Tech/Sci/R&D Officer bei PIERIS PHARMACEUTICALS, INC.
Ursprung des Netzwerks ersten Grades von Kayti Aviano
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 27 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Kayti Aviano
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Chief Tech/Sci/R&D Officer | |
| GT BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| TRANSGENE | Biotechnology | Director/Board Member Director/Board Member | |
Citigroup Alternative Investments LLC
 Citigroup Alternative Investments LLC Investment ManagersFinance Citigroup Alternative Investments LLC (CAI) is a SEC-registered asset management firm headquartered in New York City. The firm was founded in 2002 and is a wholly-owned subsidiary of Citigroup Investments, Inc., which is owned by Citigroup, Inc. (NYSE: C). CAI provides advisory services to private investment companies, such as private equity funds and funds of one or more private equity and real estate funds. The investors in the funds advised by the firm are institutional investors, funds of funds, high-net worth individuals and employees, and former employees of Citigroup, Inc. | Investment Managers | Portfolio Manager-Equities | |
| SANOFI | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Operating Officer | |
| ACCELERON PHARMA INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Biotechnology | Director/Board Member | |
Lombard Odier Asset Management (USA) Corp.
 Lombard Odier Asset Management (USA) Corp. Investment ManagersFinance Lombard Odier Asset Management (USA) Corp. (LOAM) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2000 and do-business-as Lombard Odier Investment Managers. The firm is a subsidiary of LO Holding SA and their ultimate parent is Switzerland-based Compagnie Lombard Odier SCmA. LOAM provides investment advisory services on a discretionary basis to private pooled investment vehicles (Funds) and investment advisory accounts. The investors in the Funds consist of endowments, foundations, insurance companies, high net-worth individuals, funds of funds, public and corporate pensions, and other sophisticated investors. | Investment Managers | Portfolio Manager-Equities | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| MORPHOSYS AG | Biotechnology | General Counsel Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| Grove City College | College/University | Undergraduate Degree | |
| University of Toronto | College/University | Doctorate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Corporate Officer/Principal | |
| AMBRX INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| SUCAMPO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Intermediate Capital Group Plc (Private Equity)
 Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance Intermediate Capital Group Plc (Private Equity) (ICG) is a private equity division of Intermediate Capital Group Plc founded in 1989. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| George Washington University Law School | College/University | Graduate Degree | |
| CUE BIOPHARMA, INC. | Biotechnology | Director/Board Member | |
| NEXTCURE, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
Pieris Pharmaceuticals GmbH
 Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The private company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
| FOGHORN THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO | |
| DECIPHERA PHARMACEUTICALS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Biotechnology | Chief Executive Officer | |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Investment Managers | Private Equity Investor | |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Packaged Software | Director/Board Member | |
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Biotechnology | Director/Board Member | |
| PRIME MEDICINE, INC. | Biotechnology | Director of Finance/CFO | |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Investment Managers | Consultant / Advisor | |
OnCusp Therapeutics6
 OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | Miscellaneous Commercial Services | Director/Board Member | |
Itolerance, Inc.
 Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Biotechnology | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 35 |
| Vereinigtes Königreich | 5 |
| Kanada | 4 |
| Deutschland | 4 |
| Frankreich | 3 |
Sektoral
| Health Technology | 29 |
| Finance | 13 |
| Consumer Services | 6 |
| Commercial Services | 4 |
| Technology Services | 3 |
Operativ
| Director/Board Member | 123 |
| Corporate Officer/Principal | 62 |
| Independent Dir/Board Member | 45 |
| Director of Finance/CFO | 26 |
| Chief Tech/Sci/R&D Officer | 22 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Peter Kiener | 25 |
| James Geraghty | 25 |
| Darlene M. Deptula-Hicks | 24 |
| Jean Bizzari | 24 |
| Julian Adams | 22 |
| Matthew Sherman | 16 |
| Michael Richman | 16 |
| Steven Prelack | 15 |
| Allan Reine | 14 |
| Lance Thibault | 11 |
| Christopher Kiritsy | 10 |
| Ann J. Barbier | 9 |
| Hitto Kaufmann | 9 |
| Maya Said | 8 |
- Börse
- Insiders
- Kayti Aviano
- Unternehmensverbindungen
